Cutia Therapeutics announced NMPA clearance to initiate a clinical study for CU-40105, a topical dutasteride formulation, for the treatment of androgenetic alopecia (AGA). The 5α-reductase inhibitor, which blocks both type I and type II enzymes to prevent testosterone-to-DHT conversion in the scalp, offers a localized delivery approach designed to minimize systemic exposure and associated side effects compared to oral dutasteride, which is approved for AGA in multiple global markets but carries systemic safety considerations.
Regulatory Milestone
Item
Detail
Agency
National Medical Products Administration (NMPA)
Approval Type
Clinical trial authorization (IND)
Product
CU-40105
Drug Class
Topical dutasteride formulation
Mechanism
Competitive inhibitor of type I and type II 5α-reductase
Indication
Androgenetic alopecia (AGA)
Developer
Cutia Therapeutics (China-based)
Differentiation
Topical vs. oral delivery; reduced systemic exposure
Approval Date
16 Mar 2026
Drug Profile & Mechanism
Attribute
CU-40105 Specification
Active Ingredient
Dutasteride
Formulation
Topical (scalp application)
Target Enzymes
5α-reductase type I and type II (dual inhibition)
Mechanism of Action
Inhibits testosterone → dihydrotestosterone (DHT) conversion in scalp
Therapeutic Effect
Reduces DHT-mediated miniaturization of hair follicles; promotes hair growth
Key Advantage
Localized action; minimal systemic absorption; reduced side effect profile
Scientific Rationale:
DHT and AGA: Dihydrotestosterone is the primary androgen driving hair follicle miniaturization in genetically susceptible individuals
Dual 5α-Reductase Inhibition: Dutasteride blocks both isoforms (vs. finasteride – type II only) → more complete DHT suppression
Topical Advantage: Direct scalp delivery vs. oral systemic circulation; potential for comparable efficacy with improved safety
Market Context & Strategic Value
Factor
Implication
AGA Market Size
China: 250+ million affected men and women; significant cosmetic and psychological impact
Non-inferiority/superiority vs. oral dutasteride or finasteride
Regulatory Strategy
2031-2032
China NDA; U.S./EU 505(b)(2) pathway leveraging oral dutasteride safety database
Commercial Launch
2032+
Dermatology/aesthetic medicine distribution; direct-to-consumer marketing
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical development timelines, topical formulation efficacy, and competitive positioning for CU-40105 in androgenetic alopecia. Actual results may differ due to formulation stability, scalp penetration optimization, and competitive dynamics with established oral therapies.-Fineline Info & Tech
By Fineline Cube